![](https://canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBc1FGIiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--e07aebdfa19e8cdfd0d815eec57767a677db4700/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/Transposon.png)
Transposon Therapeutics
Transposon Therapeutics, Inc. is developing TPN-101 (also known as Censavudine) and other LINE-1 reverse transcriptase inhibitors for the treatment of rare neurodegenerative diseases such as progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Aicardi-Goutières Syndrome (AGS).